5 Key Takeaways

• 1

  Lecanemab activates brain immune cells via its Fc fragment, enhancing the clearance of amyloid plaques in Alzheimer's disease.

• 2

  The Fc portion of lecanemab acts as a molecular switch, engaging microglial receptors to trigger plaque degradation.

• 3

  Lecanemab induces a specific microglial gene expression program linked to phagocytosis and lysosomal degradation.

• 4

  The drug's activation of microglia does not cause excessive synapse loss, preserving surrounding neural structures.

• 5

  Future strategies may involve fine-tuning Fc interactions or directly stimulating microglial pathways for safer treatments.